Tammy

Next Post

Synlogic Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Sat Mar 19 , 2022
Synlogic, Inc. – Phenylketonuria (PKU) program on track for Phase 3 trial initiation in H2 2022 – – Clinical readouts anticipated for PKU program in H1 2022 and in homocystinuria and enteric hyperoxaluria in H2 2022 – – $136.6 million in cash, cash equivalents and marketable securities support projected runway […]